RxDoctor Payments Data

David Lin, MD

Family Medicine · Sacramento, CANPI 1356446819

Payments from drug & device makers

$1,920in general payments, 2019–2025

Across 17 payments — averaging $112.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cepheid$1K
  • AstraZeneca$221
  • Nestle Healthcare Nutrition Inc.$125
  • Biohaven Pharmaceuticals, Inc.$122
  • Medtronic$82
  • Boston Scientific$78
  • plus $91 from 2 others

What the payments were for

  • Speaking & faculty fees$1,20163%
  • Food & beverage$71937%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,920 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$80,061
Medicare patients
243
Services billed
736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin47$64,349
EliquisApixaban49$63,732
OzempicSemaglutide36$61,688
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$39,662
FarxigaDapagliflozin Propanediol11$13,860
TrulicityDulaglutide11$13,806
Incruse ElliptaUmeclidinium Bromide21$11,924
Breo ElliptaFluticasone/Vilanterol18$9,600
Azelastine Hcl87$5,600
Losartan Potassium326$4,380
Gabapentin102$3,434
Levothyroxine Sodium174$3,083
Fluticasone Propionate87$2,920
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen93$2,771
Pravastatin Sodium150$2,588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$221$13,86011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Sacramento

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →